2-[4-(Pyrimidin-2-yl)piperazin-1-yl]pyrimidine

Catalog No. :
ACNRXH408
CAS No. :
84746-24-7
Molecular Formula :
C12H14N6
Molecular Weight :
242.29

IUPAC Name:1,4-di(pyrimidin-2-yl)piperazine

2-[4-(Pyrimidin-2-yl)piperazin-1-yl]pyrimidine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$156.00Login to see priceIn stockIn stock
250mg95%$234.00Login to see priceIn stockIn stock
1g95%$587.00Login to see priceIn stockInquiry
5g95%$2219.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-[4-(Pyrimidin-2-yl)piperazin-1-yl]pyrimidine
IUPAC Name1,4-di(pyrimidin-2-yl)piperazine
MDL No.MFCD04208147
Molecular FormulaC12H14N6
Molecular Weight242.29
SMILESC1(N2CCN(C3=NC=CC=N3)CC2)=NC=CC=N1
InChI KeyCGDIIYVMINKXRL-UHFFFAOYSA-N
Synonym2-(4-pyrimidin-2-ylpiperazin-1-yl)pyrimidine;Buspirone Impurity 7(Buspirone EP Impurity G);Buspirone EP Impurity G;1,4-di-pyrimidin-2-yl-piperazine;Buspirone EP Imp G;Pipidil Impurity 1 (Tanduropirone Impurity 1);2,2'-(Piperazine-1,4-diyl)dipyrimid;Piribedil Impurity 1(Tandospirone Impurity 1)
CAS No.84746-24-7
PubChem CID3228611

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACNRXH408 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACRKMW197 route compound structure diagram
    ACRKMW19778069-54-2 In Stock
  4. Then
  5. ACNRXH408 route product structure diagram
    ACNRXH40884746-24-7 In Stock
Inquiry

2. ACNRXH408 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACNRXH408 route product structure diagram
    ACNRXH40884746-24-7 In Stock
Inquiry

Comments (0)